Ace Vision Group, Inc., a leading medical device company at the forefront of pioneering laser rejuvenation therapy for the aging eye, today announced that it has named Rob Kissling, MD as chief medical officer.
Dr. Kissling has over 20 years of experience integrating clinical development, medical strategy, and business planning to develop and commercialize best-in-class devices and medicines for ophthalmology.
His tenure has included companies such as Pharmacia, Pfizer, and Novartis. Most recently, he served as vice president of Clinical and Medical Affairs at Bausch and Lomb, where he oversaw medical development of the company’s pharmaceutical, surgical, and consumer product portfolio.
At Ace Vision Group, Dr. Kissling will apply his expertise to the development and commercialization of Laser Scleral Microporation(LSM)—a microporation therapeutic for the aging eye to rejuvenate visual age lost by presbyopia.
“I see enormous potential for the role of laser scleral microporation,” said Dr. Kissling, “and I will diligently work with the Ace Vision Group to clinically prove and commercially establish laser scleral microporation as a first-in-class solution for presbyopia and other relevant conditions.”
“We are excited to welcome Dr. Kissling as we pursue our commitment to creating innovative solutions that address age-related eye conditions,” said Dr. AnnMarie Hipsley, CEO of Ace Vision Group. “Dr. Kissling’s expertise in both the clinical and commercial aspects of ophthalmology product lines make him an ideal addition to our team as we work with leading eye care professionals, building towards the next revolution in eye care.”
About Ace Vision Group
Ace Vision Group, Inc, is an emerging ophthalmic laser device company focused on bringing innovative touchless Eye Laser Therapy to patients suffering from age-related vision loss.
The company is focused on the development and commercialization of its first product, the VisioLite Ophthalmic Laser, a touchless therapeutic device.
The initial use for this device is Laser Scleral Microporation (LSM), a clinical-stage minimally invasive rejuvenation therapy for the treatment of presbyopia and potentially other eye diseases, including glaucoma.